NASDAQ OMX

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA

Dela

Pressmeddelande

7 november 2017

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA

Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att man presenterar resultaten från en preklinisk studie utformad för att ge ytterligare data kring verkningsmekanismen  hos Immunicums ledande läkemedelskandidat ilixadencel om det ledande programmet ilixadencels verkningssätt. De prekliniska resultaten visar hur ilixadencel genererar komplementära immunologiska processer som är nödvändiga för att lära immunsystemet att känna igen och avdöda cancerceller. Resultaten kommer att presenteras som en poster vid SITCs 32:a årsmöte som hålls den 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland.

Immunicum, i samarbete med professor Magnus Essands forskningsgrupp vid Uppsala universitet, genomförde en rad cellodlingsexperiment avsedda att efterlikna de immunologisk processer som uppstår när ilixadencel injiceras intratumoralt och börjar interagera med en cancerpatients immunsystem.

Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras den 11 november kl. 12.30 EST av Alex Karlsson-Parra.

Enligt vad som framkom så induceras följande immunologiska processer:

  1. Ilixadencel, när det odlas enskilt, producerade avsevärda mängder cellsignalerande molekyler (kemokiner och cytokiner) som är avgörande för att attrahera och aktivera viktiga immunceller, särskilt patientens dendritceller, NK celler (naturliga mördarceller) och T celler.
  2. När Ilixadencel odlades tillsammans med NK celler ledde detta till en kraftig produktion av interferon-gamma hos NK cellerna, en viktig stimulerande faktor som krävs för aktivering av tumörspecifika mördar-T-celler.
  3. Ilixadencel visade sig också inducera en signifikant ökad förmåga hos NK cellerna att döda tumörceller.
  4. De specifika inflammatoriska faktorer som producerades när ilixadencel odlades tillsammans med immunceller visade sig dessutom kunna inducera en fenotypisk och funktionell utmognad av dendritceller, vilka spelar en viktig roll i att hjälpa immunsystemet att specifikt känna igen tumörceller.

Genom att aktivera dessa kompletterande mekanismer ökar ilixadencel immunsystemets kapacitet att effektivare känna igen och döda tumörceller.

- Vi tycker att det är mycket spännande med dessa fynd som breddar vår förståelse för ilixadencels underliggande verkningsmekanismer och stämmer överens med vad vi tidigare sett, säger Alex Karlsson-Parra, Immunicums forskningschef.

- Ilixadencels förmåga att aktivera NK celler till högeffektiva tumörcellsmördare är av särskilt intresse, eftersom tumörcellsdöd orsakad av NK celler är känd för att underlätta efterföljande aktivering av tumörspecifika T celler. Vi är glada över att kunna dela med oss av dessa upptäckter till forskare och den medicinska världen som deltar i SITC-mötet.

Resuméer om konferensen innehåll publicerades i dag på SITCs hemsida. Hela postern kommer att vara tillgänglig på Immunicums hemsida efter presentationen via denna länk: http://immunicum.se/investors/downloads/

Immunicums ledande program ilixadencel är för närvarande under klinisk utveckling i en pågående Fas 2-studie i njurcancer (MERECA) samt Fas 1/2-studie i gastrointestinala stromacellstumörer och Fas 1/2-studier i njurcancer och primär levercancer har framgångsrikt genomförts med en lovande säkerhetsprofil och belägg för tumörspecifik immunaktivering hos merparten av patienterna.

Om ilixadencel
Cellterapiprodukten ilixadencel (tidigare kallad INTUVAX®) är en cancerimmunaktiverare som kan lagras "på hylla" ("off-the-shelf") och som utvecklats för behandling av solida tumörer. Den aktiva ingrediensen är aktiverade allogena dendritceller som tas från friska blodgivare. Intratumoral injektion med dessa celler förväntas leda till en inflammatorisk respons som i sin tur leder till en tumörspecifik aktivering av patientens cytotoxiska T-lymfocyter.

 

För ytterligare information kontakta:

Carlos de Sousa, VD, Immunicum
Telefon: +46 (0) 31 41 50 52
E-post: info@immunicum.com

Investor Relations, Sverige

Helena Stångberg
Hallvarsson & Halvarsson
Telefon: + 46 709 71 12 53
E-post: ir@immunicum.com

Mediakontakt

MacDougall Biomedical Communications
Gretchen Schweitzer eller Stephanie May
Telefon: +49 89 2424 3494 eller +49 175 5711562
E-post: ir@immunicum.com

Bolagets Certified Adviser är Redeye AB
Telefon: +46 (0)8 545 013 30www.redeye.se

 

Om Immunicum AB (publ)

Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet. Företagets ledande produkt, ilixadencel, bestående av pro-inflammatoriska allogena dendritiska celler, har potentialen att bli en grundstomme i modern kombinationsbehandling av ett flertal olika solida tumörformer. Immunicum är grundat och baserat i Sverige och är noterat på First North Premier. www.immunicum.com

 

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Northland Power Announces Retirement of CEO John Brace and Appointment of Mike Crawley as Chief Executive Officer, Effective August 4, 201823.5.2018 01:27Pressmeddelande

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that Chief Executive Officer John Brace will retire on August 4, 2018 after 30 years with the company. Mike Crawley, currently Northland's Executive Vice President, Development has been appointed to the role of Chief Executive Officer, effective August 4, 2018. Mr. Brace and Mr. Crawley will work together to ensure a smooth transition. Mr. Brace will continue to serve as a Director of Northland. John joined Northland in 1988, shortly after the company was founded. He was appointed Chief Executive Officer in 2005. He has steered Northland through many of its projects, initiatives and growth. Under his leadership, the company has grown to its current enterprise value of $12 billion. John was appointed to Northland's Board of Directors on April 4, 2018, and along with Northland's other board members, will stand for re-election at Northland's Annual General Meeting on May 23rd, 2018. Mike

MyoGen: Leaders of an Anabolic Revolution22.5.2018 23:00Pressmeddelande

GUJARAT, India, May 23, 2018 (GLOBE NEWSWIRE) -- Myogen will make you rethink what the human body is capable of. To be an athlete means to partake on a never-ending quest for self-improvement. An obsession to search for a winning edge. Even when we are competing against ourselves, our desire to overcome our physical limitations and achieve new heroic and record setting performances becomes an overwhelming primary focus. Today marks an evolution in what the human body is capable of, with the launch of the MyoGen range of anabolic products. Myogen, the essence of "muscles". MyoGen takes its source from the Greek words "Myo" meaning "Muscle" and "Genesis" meaning "Birth". This implicit historical reference, of the origin of the muscle, displays both the commitment and professionalism of Myogen, and their unwavering focus on peak physical performance. The brightest leader's blaze trails. The Myogen brand is managed by an international team of experts who are committed to making athletes st

Constellation Brands Promotes Jim Sabia to Newly Created Role of Chief Marketing Officer22.5.2018 22:30Pressmeddelande

New role will serve as a member of the company's Executive Management Committee VICTOR, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that it has promoted Jim Sabia to the newly created role of Executive Vice President and Chief Marketing Officer, Constellation Brands. In this new role, Sabia will serve as the marketing lead for the company's Beer and Wine & Spirits Divisions, responsible for all aspects of marketing across Constellation's entire beverage alcohol portfolio. Sabia will serve as a member of the company's Executive Management Committee and report directly to Bill Newlands, President and Chief Operating Officer. "Our company's core mission is to build brands consumers love and Jim has been a driving force behind the success of our beer brands over the years," said Newlands. "It is critically important that the voice of the consumer and brand-building principles have strong repr

Algeco Announces First Quarter 2018 Financial Results Conference Call22.5.2018 17:52Pressmeddelande

BALTIMORE, May 22, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, "Algeco"), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its first quarter 2018 financial results conference call on Tuesday, June 5, 2018 at 10:00 a.m., Eastern Time. To access the call, please dial (847) 585-4422 or (888) 424-8151 (US toll free) and enter participant PIN code 9192211# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to http://web.meetme.net/r.aspx?p=2&a=UTzMrdwdRriEIu. Please enter your name, email address and company to join the call. The customer service team can be reached at any time by pressing *0 on your telephone keypad. On Wednesday, May 30, 2018 at

Hitachi Named a Visionary in Inaugural Gartner Magic Quadrant for Industrial IoT Platforms22.5.2018 15:00Pressmeddelande

Hitachi Positioned in Visionaries Quadrant for Completeness of Vision and Ability To Execute TOKYO and SANTA CLARA, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) and Hitachi Vantara, today announced that Hitachi has been positioned in the Visionaries quadrant of the inaugural Gartner Magic Quadrant for Industrial IoT Platforms1based on Gartner, Inc.'s evaluation of the company, which included Hitachi's Lumada IoT platform. Gartner describes the market for IIoT platforms as "a set of integrated software capabilities. These capabilities span efforts to improve asset management decision-making, as well as operational visibility and control for plants, depots, infrastructure and equipment within asset-intensive industries." In the report, Gartner predicts: "By 2020, on-premises Internet of Things (IoT) platforms coupled with edge computing will account for up to 60% of industrial IoT (IIoT) analytics, up from less than 10% today." The report also notes: "Gartner believe

Cemtrex SmartDesk Now Available for Preorder22.5.2018 14:30Pressmeddelande

Cemtrex Launches SmartDesk to Reinvent the Personal Workspace and Revolutionize Desktop Workstation Productivity FARMINGDALE, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Cemtrex Inc. (Nasdaq:CETX) (Nasdaq:CETXP) (Nasdaq:CETXW), a world leading technology and manufacturing company, today announced the launch of the Cemtrex SmartDesk, the most advanced workstation on the market. The SmartDesk is a blend of futuristic hardware and groundbreaking productivity software, delivering the next generation desktop experience in a luxurious package, and Cemtrex is now taking preorders. "The world is ready for a SmartDesk. It is 2018 but our workspaces have not evolved like most things we interact with on a daily basis like our smartphones, smart cars and smart homes," said Cemtrex's CEO and Chairman, Saagar Govil. "With the SmartDesk we intend to transform and disrupt the $500 billion annual PC market globally, as it will streamline workflows, improve productivity with its many features, and provide su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum